Labile plasma iron, more practical and more sensitive to iron overload in myelodysplastic syndromes

References

• Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19):1872–85. doi: 10.1056/NEJMra0902908
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Laarakkers CM, Galli A, Albertini R, Maffioli M, et al. Erythroid activity, transfusion iron overload, and hepcidin levels in patients with myelodysplastic syndrome. Blood 2008;112(11): 2676a (ASH annual meeting abstracts).
   PubMed Web of Science ®Google Scholar
• Gattermann N, Rachmilewitz EA. Iron overload in MDS—pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90(1):1–10. doi: 10.1007/s00277-010-1091-1
   PubMed Web of Science ®Google Scholar
• Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Galli A, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica 2013;98(3):420–3. doi: 10.3324/haematol.2012.077446
   PubMed Web of Science ®Google Scholar
• Hershko C, Graham G, Bates GW, Rachmilewitz E. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40(2):255–63. doi: 10.1111/j.1365-2141.1978.tb03662.x
   PubMed Web of Science ®Google Scholar
• Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol. 2003;77(4):342–50. doi: 10.1007/BF02982641
   PubMed Web of Science ®Google Scholar
• Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 2008;88(1):7–15. doi: 10.1007/s12185-008-0120-5
   PubMed Web of Science ®Google Scholar
• Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277–87. doi: 10.1016/j.beha.2004.10.003
   PubMed Web of Science ®Google Scholar
• Jensen PD, Jensen IM, Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol. 1992;80(1):121–4. doi: 10.1111/j.1365-2141.1992.tb06411.x
   PubMed Web of Science ®Google Scholar
• St. Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105(2):855–61. doi: 10.1182/blood-2004-01-0177
   PubMed Web of Science ®Google Scholar
• Armand P, Kim H, Rhodes J, Sainvil M-M, Cutler C, Ho VT, et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(6):852–60. doi: 10.1016/j.bbmt.2010.09.006
   PubMed Web of Science ®Google Scholar
• Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89(1):87–93. doi: 10.1111/j.1600-0609.2012.01783.x
   PubMed Web of Science ®Google Scholar
• Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of nontransferrin-bound plasma iron with deferoxamine therapy. Blood 1996;88(2):705–13.
   PubMed Web of Science ®Google Scholar
• Gattermann N. Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators. Hematol Oncol Clin North Am. 2005;19(Suppl. 1):13–17.
   Google Scholar
• Fragasso A, Ciancio A, Mannarella C, Gaudiano C, Scarciolla O, Ottonello C, et al. Myocardial iron overload assessed by magnetic resonance imaging (MRI)T2* in multi-transfused patients with thalassemia and acquired anemias. Eur J Intern Med. 2011;22(1):62–65. doi: 10.1016/j.ejim.2010.10.005
   PubMed Web of Science ®Google Scholar
• Cheng HL, Holowka S, Moineddin R, Odame I. Liver iron overload assessment by T2* magnetic resonance imaging in pediatric patients: an accuracy and reproducibility study. Am J Hematol. 2012;87(4):435–7. doi: 10.1002/ajh.23114
   PubMed Web of Science ®Google Scholar
• Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986;6(1):24–29. doi: 10.1002/hep.1840060106
   PubMed Web of Science ®Google Scholar
• Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 2005;112(4):535–43. doi: 10.1161/CIRCULATIONAHA.104.504415
   PubMed Web of Science ®Google Scholar
• Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51(2):209–21. doi: 10.1016/0002-9343(71)90240-3
   PubMed Web of Science ®Google Scholar
• Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304(6):319–24. doi: 10.1056/NEJM198102053040603
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–9. doi: 10.1053/euhj.2001.2822
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348–55. doi: 10.1111/j.1365-2141.2004.05202.x
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Cattaneo C, Cristiani S, Duca L, Sarina B, Deliliers GL. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J. 2000;1(3):153–8. doi: 10.1038/sj.thj.6200028
   PubMedGoogle Scholar
• Tanno T, Bhanu NV, Oneal PA, Goh S-H, Staker P, Lee YT. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096–101. doi: 10.1038/nm1629
   PubMed Web of Science ®Google Scholar
• Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One 2011;6(8):e23109. doi: 10.1371/journal.pone.0023109
   PubMed Web of Science ®Google Scholar
• Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010;17(3):184–90.
   PubMed Web of Science ®Google Scholar